Thymidylate synthase (TYMS) and UGT1A germline polymorphisms influence the therapeutic outcome of colorectal cancer (CRC) patients treated with irinotecan plus 5-fluorouracil (irinotecan/5FU). This evidence concerns the gene TYMS and colorectal carcinoma.